<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00259623</url>
  </required_header>
  <id_info>
    <org_study_id>0406902</org_study_id>
    <secondary_id>AOL</secondary_id>
    <nct_id>NCT00259623</nct_id>
  </id_info>
  <brief_title>Cardiac Surgical Treatment by Radiofrequency Ablation on Valvular Patients: Efficacy at 3 Months</brief_title>
  <official_title>Efficacy at 3 Months on Permanent Atrial Fibrillation in Patients Candidates to Cardiac Surgical Treatment by Epicardial, or Possibly Endocardial, Radiofrequency Ablation</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital, Toulouse</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University Hospital, Toulouse</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The objective of the study is to evaluate the efficacy of the epicardial or endocardial&#xD;
      radiofrequency ablation in the treatment of atrial fibrillation.&#xD;
&#xD;
      It is a multicentric, prospective, randomized, parallel, comparative, double blind study. The&#xD;
      study principal objective is to evaluate the absence of atrial fibrillation after 3 months.&#xD;
      The secondary objectives consist in the evaluation of the maintenance of the sinusal heart&#xD;
      rate at one year and of the quality of life improvement&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Principal objective:&#xD;
&#xD;
      To evaluate the efficacy at 3 months of combined ablation technique in the treatment of&#xD;
      chronic atrial fibrillation during cardiac surgery in order to obtain a sinusal heart rate.&#xD;
&#xD;
      A sequential statistical analysis of the results will be performed every 10 patients.&#xD;
&#xD;
      In case of validation of the principal objective by a sequential method i.e. proving the&#xD;
      superiority of the treatment by ablation, ,the study would then be opened and pursued by&#xD;
      using the ablation technique for all subsequent patients in order to validate the secondary&#xD;
      study objectives&#xD;
&#xD;
      Secondary objectives:&#xD;
&#xD;
        -  To evaluate the quality of life of the patients at one year and the absence of atrial&#xD;
           fibrillation relapse.&#xD;
&#xD;
        -  6 and 12 months clinical follow-up&#xD;
&#xD;
        -  To evaluate the left atrial function at 6 months by trans-oesophagus echocardiography&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>December 2005</start_date>
  <completion_date type="Actual">October 2007</completion_date>
  <primary_completion_date type="Actual">October 2007</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>- absence of atrial fibrillation at 3 months.</measure>
  </primary_outcome>
  <primary_outcome>
    <measure>The patients presenting a spontaneous sinus rhythm heart rate or who need a permanent pace maker at 3 months will be considered as SUCCESSFUL.</measure>
  </primary_outcome>
  <primary_outcome>
    <measure>The patients presenting at 3 months either an atrial fibrillation or a left flutter despite an adapted anti-arrythmia treatment and one electric cardioversion,and the patients who died before the 3 months evaluation will be considered as FAILURES</measure>
  </primary_outcome>
  <enrollment type="Actual">13</enrollment>
  <condition>Atrial Fibrillation</condition>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Radiofrequency ablation</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Adult patients with no age limit, presenting a chronic atrial fibrillation and planned&#xD;
             to undergo a surgical intervention on mitral valve (valve replacement or plasty)&#xD;
             associated or not with myocardial revascularization or replacement/plasty of another&#xD;
             valve (aortic, tricuspid)&#xD;
&#xD;
          -  The chronic atrial fibrillation is defined as a continuous atrial fibrillation more&#xD;
             than 1 month before the surgery despite all anti-arrhythmia treatments including&#xD;
             cardioversion ; the atrial fibrillation can be associated to another rhythm trouble&#xD;
             except the severe ventricular rhythm troubles.&#xD;
&#xD;
          -  The indication for surgery is performed using the clinical evaluation : NYHA &gt;2 and&#xD;
             the usual echocardiography criteria (mitral regurgitation &gt; grade 3, mitral gradient&#xD;
             &gt;10 mm Hg or valve surface &lt; 1,5 cm2)&#xD;
&#xD;
          -  Patients with a vital prognosis not compromised by comorbidity in the next 2 years and&#xD;
             with a mental state enabling to give informed consent&#xD;
&#xD;
          -  Patients agreeing to take part in the study and having signed the informed consent&#xD;
             form.&#xD;
&#xD;
        For the part of the study pursued in open independent to the actual protocol, patients&#xD;
        having signed the modified informed consent with approval of the new study procedure not&#xD;
        yet published.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Paroxystic atrial fibrillation or atrial fibrillation for less than 1 month&#xD;
&#xD;
          -  Atrial fibrillation never treated by cardioversion or pharmacology before surgery.&#xD;
&#xD;
          -  Contra-indication to surgery, i.e. severe respiratory failures, multivisceral&#xD;
             deficiencies (renal, cardiac or hepatic), rapidly evolutive or metastatic cancers,&#xD;
             malignant hemopathies not stabilized by chemotherapy&#xD;
&#xD;
          -  Contra-indication to the following arrhythmia treatments: class III (amiodarone)&#xD;
             associated to contra-indication to class II (beta blockers) or to class Ic&#xD;
             (flecainide, propafenone, cibenzoline).&#xD;
&#xD;
          -  Severe decompensated heart failure.&#xD;
&#xD;
          -  Uncontrolled, repetitive, severe documented ventricular arrhythmia (ventricular&#xD;
             tachycardia, ventricular fibrillation episodes)&#xD;
&#xD;
          -  Contra indication to epicardic ablation procedure (pericardic adhesions, intra-atrial&#xD;
             thrombus) In these cases the ablation could be only an endocardic ablation but it does&#xD;
             not necessarily exclude the patient.&#xD;
&#xD;
          -  Ventricular &quot;ejection fraction &quot; &lt; 40%&#xD;
&#xD;
          -  Impossibility to follow the pre-inclusion phases i.e. emergency surgery for mitral&#xD;
             break or evolutive endocarditis.&#xD;
&#xD;
          -  Patients with disabled mental status&#xD;
&#xD;
          -  Patient participating in another clinical study&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Gérard FOURNIAL, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University Hospital, Toulouse, France</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Service de Chirurgie Cardio-Vasculaire - Hôpital Côte de Nacre</name>
      <address>
        <city>Caen</city>
        <zip>14033</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Service de Chirurgie Cardio-Vasculaire - Hôpital Gabriel Montpied</name>
      <address>
        <city>Clermont-Ferrand</city>
        <zip>63003</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Service de Chirurgie Cardio-vasculaire - CHU Dupuytren</name>
      <address>
        <city>Limoges</city>
        <zip>87042</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Service de Chirurgie Cardio Vasculaire - CHU RANGUEIL</name>
      <address>
        <city>Toulouse</city>
        <zip>31059</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Service de Chirurgie Cardio Vasculaire - Clinique Pasteur</name>
      <address>
        <city>Toulouse</city>
        <zip>31076</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <reference>
    <citation>Benussi S, Nascimbene S, Agricola E, Calori G, Calvi S, Caldarola A, Oppizzi M, Casati V, Pappone C, Alfieri O. Surgical ablation of atrial fibrillation using the epicardial radiofrequency approach: mid-term results and risk analysis. Ann Thorac Surg. 2002 Oct;74(4):1050-6; discussion 1057.</citation>
    <PMID>12400744</PMID>
  </reference>
  <results_reference>
    <citation>Raman JS, Ishikawa S, Power JM. Epicardial radiofrequency ablation of both atria in the treatment of atrial fibrillation: experience in patients. Ann Thorac Surg. 2002 Nov;74(5):1506-9.</citation>
    <PMID>12440600</PMID>
  </results_reference>
  <verification_date>July 2009</verification_date>
  <study_first_submitted>November 25, 2005</study_first_submitted>
  <study_first_submitted_qc>November 25, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 29, 2005</study_first_posted>
  <last_update_submitted>July 16, 2009</last_update_submitted>
  <last_update_submitted_qc>July 16, 2009</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 17, 2009</last_update_posted>
  <responsible_party>
    <name_title>Roques</name_title>
    <organization>University Hospital Toulouse</organization>
  </responsible_party>
  <keyword>Cardiac surgery</keyword>
  <keyword>Radiofrequency ablation</keyword>
  <keyword>Atrial fibrillation</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Atrial Fibrillation</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

